NasdaqGS - Nasdaq Real Time Price ? USD Gilead Sciences, Inc. (GILD) Follow Compare 86.75 +0.93 (+1.08%) At close: October 16 at 4:00 PM EDT 86.36 -0.39 (-0.45%) Pre-Market: 6:35 AM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts Gilead Sciences (GILD) reachead $85.83 at the closing of the latest trading day, reflecting a +0.91% change compared to its last close. Zacks ? yesterday GILD +1.08% How Brookfield Infrastructure, Invitation Homes And Gilead Sciences Can Put Cash In Your Pocket Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Brookfield Infrastructure Partners, Invitation Homes and Gilead Sciences have rewarded their shareholders for several decades ... Benzinga ? 2 days ago BIP-PA GILD +1.08% INVH Is Gilead Sciences, Inc. (NASDAQ:GILD) The Most Popular Stock Among Mutual Funds According To Goldman Sachs? We recently made a list of Goldman Sachs’ List Of Stocks Popular With Mutual Fund Managers: Top 20 Stocks. In this piece, we will look at where Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the list of stocks that mutual funds are buying according to Goldman Sachs. As the fourth quarter of 2024 starts, the market […] Insider Monkey ? 6 days ago GILD +1.08% Gilead Sciences Inc (GILD) Q2 2024 Earnings Call Highlights: Strong Growth in HIV and Oncology ... Gilead Sciences Inc (GILD) reports robust financial performance with significant sales growth in key therapeutic areas and raises full-year guidance. GuruFocus.com ? 7 days ago GILD +1.08% Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024 FOSTER CITY, Calif., October 09, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2024 financial results and guidance will be released on Wednesday, November 6, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2024 financial results and provide a business update. Business Wire ? 7 days ago GILD +1.08% Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024 FOSTER CITY, Calif., October 09, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research and development programs at IDWeek 2024, taking place from October 16-19. The data from 31 presentations across HIV treatment and prevention, COVID-19 and viral hepatitis include one late breaker abstract and six oral presentations, reflecting Gilead’s commitment to helping address the evolving needs of a diverse range of people and com Business Wire ? 7 days ago GILD +1.08% Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know Gilead Sciences (GILD) reachead $85.21 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close. Zacks ? 8 days ago GILD +1.08% Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference FOSTER CITY, Calif., October 07, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752) providing an overview of the efficacy and safety of twice-yearly lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people. Business Wire ? 9 days ago GILD +1.08% AstraZeneca and Gilead Sciences merger would be the biggest in the pharma history The Speculation Around an AstraZeneca-Gilead Merger AstraZeneca, the UK’s largest drugmaker valued at $140bn, has reportedly contacted Gilead Sciences, an American biopharmaceutical company with a market value of approximately $96bn, regarding a possible merger deal. The approach was supposedly informal and aimed at testing its US rivals interest in the deal. Gilead has previously focused… Pharmaceutical Technology ? 10 days ago AZN +0.59% GILD +1.08% Gilead Sciences' (NASDAQ:GILD) investors will be pleased with their favorable 62% return over the last five years When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore... Simply Wall St. ? 11 days ago GILD +1.08% Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last? Praxis Precision Medicines (PRAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. Zacks ? 12 days ago PRAX GILD +1.08% GILD Grants Right for HIV PrEP Candidate to Six Generic Companies Gilead signs non-exclusive, royalty-free voluntary licensing agreements with six generic companies to market its investigational medicine, lenacapavir, for HIV Prevention. Zacks ? 13 days ago GILD +1.08% Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store. Zacks ? 13 days ago GILD +1.08% Gilead signs agreements to facilitate access to HIV prevention drug The move aligns with Gilead's strategy to ensure the availability of lenacapavir worldwide for PrEP. Pharmaceutical Technology ? 14 days ago GILD +1.08% Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries Hetero, India's leading pharmaceutical company with the widest global reach, today announced a new partnership with Gilead Sciences Ireland UC (Gilead Sciences, (Nasdaq: GILD)), a non-exclusive, royalty-free voluntary licensing agreement to manufacture and distribute lenacapavir in 120 primarily low- and lower- middle income countries (LMICs). This agreement will broaden access to lenacapavir, the innovative HIV treatment used in combination with other antiretrovirals and will support efforts to PR Newswire ? 14 days ago GILD +1.08% Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries FOSTER CITY, Calif., October 02, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries, which are primarily low- and lower-middle income countries. The agreements were signed in advance of any global regulatory submissions to enable these countries Business Wire ? 14 days ago GILD +1.08% Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know In the closing of the recent trading day, Gilead Sciences (GILD) stood at $83.94, denoting a +0.12% change from the preceding trading day. Zacks ? 15 days ago GILD +1.08% ^GSPC Championing HIV Services for LGBTQ+ Youth NORTHAMPTON, MA / ACCESSWIRE / September 25, 2024 / Gilead Sciences As a young gay professional, Terrell Parker spent several years working at the National Minority AIDS Council in Washington, D.C. during his 20s, advocating to help end the HIV epidemic ... ACCESSWIRE ? 21 days ago GILD +1.08% Gilead Sciences (GILD) Stock Slides as Market Rises: Facts to Know Before You Trade In the closing of the recent trading day, Gilead Sciences (GILD) stood at $83.79, denoting a -0.24% change from the preceding trading day. Zacks ? 22 days ago GILD +1.08% AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer Drug AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast cancer. Investor's Business Daily ? 23 days ago AZN +0.59% 4568.T GILD +1.08% Performance Overview Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return GILD S&P 500 YTD +10.53% +22.49% 1-Year +16.37% +35.00% 3-Year +45.25% +30.66%
